| Lipid results of partial ileal bypass in patients with heterozygous, type II-A hyperlipoproteinemia. Program on the Surgical Control of the Hyperlipidemias. | |
| | |
MedLine Citation:
|
PMID: 2120785 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Although reduction in total plasma cholesterol has yet to be shown to have a beneficial effect on overall mortality, the weight of experimental and epidemiologic evidence supports efforts to lower total plasma cholesterol levels to reduce the risk of death from coronary heart disease (CHD). This is especially true in patients with heterozygous, type II-A hyperlipoproteinemia, whose total plasma cholesterol levels above the 90th percentile for age and sex place them at markedly increased risk of death from CHD. The lipid results of partial ileal bypass (PIB) were assessed in 110 patients with heterozygous, type II-A hyperlipoproteinemia in the Program on the Surgical Control of the Hyperlipidemias, a randomized, prospective clinical trial assessing the effects of cholesterol reduction on overall mortality and the course of CHD. Compared with dietary control (n = 52), PIB (n = 58) reduced total plasma cholesterol levels 24% +/- 2% (mean +/- SEM), reduced low-density lipoprotein (LDL) cholesterol levels 34% +/- 3%, and increased high-density lipoprotein (HDL) cholesterol levels 5% +/- 5% 5 years after surgery. Very low-density lipoprotein cholesterol levels were 28% +/- 21% higher and plasma triglyceride levels were 24% +/- 11% higher in the surgical group. The HDL cholesterol/total plasma cholesterol and HDL cholesterol/LDL cholesterol ratios were significantly higher after PIB. Apolipoprotein A-I and HDL subfraction 2 levels were significantly higher and apolipoprotein B-100 levels were significantly lower in the surgical group. PIB successfully lowered mean total plasma cholesterol and LDL cholesterol levels below the limits recommended by the National Cholesterol Education Program to minimize the risk of death from CHD. These results confirm the efficacy and support the role of PIB in the management of patients with marked hypercholesterolemia. |
| | |
Authors:
|
C T Campos; J P Matts; L L Fitch; J C Speech; J M Long; H Buchwald |
Related Documents
:
|
9785055 - Detection and evaluation of dyslipoproteinemia. 9055055 - A study to determine the response of coronary atherosclerosis to raising low high densi... 3836915 - Serum lipids and lipoproteins in relation to smoking among the apparently healthy worke... 6957155 - Hyperlipoproteinemia, atherosclerosis and gemfibrozil. 8065665 - Food poverty: rowntree revisited. 7977145 - Chocolate feeding studies: a novel approach for evaluating the plasma lipid effects of ... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S. |
Journal Detail:
|
Title: Surgery Volume: 108 ISSN: 0039-6060 ISO Abbreviation: Surgery Publication Date: 1990 Oct |
Date Detail:
|
Created Date: 1990-11-02 Completed Date: 1990-11-02 Revised Date: 2007-11-14 |
Medline Journal Info:
|
Nlm Unique ID: 0417347 Medline TA: Surgery Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 601-10; discussion 610-1 Citation Subset: AIM; IM |
Affiliation:
|
Department of Surgery, University of Minnesota, Minneapolis 55455. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Apolipoprotein A-I Apolipoprotein B-100 Apolipoproteins A / blood Apolipoproteins B / blood Cholesterol / blood Cholesterol, HDL / blood Cholesterol, LDL / blood Cholesterol, VLDL / blood Female Heterozygote Humans Hyperlipoproteinemia Type II / blood, surgery* Ileum / surgery* Lipids / blood* Lipoproteins, HDL / blood Male Middle Aged Triglycerides / blood |
| Grant Support | |
ID/Acronym/Agency:
|
HL-07586/HL/NHLBI NIH HHS; HL-15265/HL/NHLBI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Apolipoprotein A-I; 0/Apolipoprotein B-100; 0/Apolipoproteins A; 0/Apolipoproteins B; 0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Cholesterol, VLDL; 0/Lipids; 0/Lipoproteins, HDL; 0/Triglycerides; 57-88-5/Cholesterol |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Radiotherapeutic quality assurance in the Hodgkin's disease study HD4 supported by the BMFT (Bundesm...
Next Document: The preservation of a DNA repair disorder in continuous-line fibroblasts obtained from gout patients